Research programme: diabetes therapeutics - MC2 TherapeuticsAlternative Names: RX-1
Latest Information Update: 24 Jan 2017
At a glance
- Originator MC2 Biotek
- Developer MC2 Therapeutics
- Class Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus